The transaminase test market is projected to grow from USD 4.4 billion in 2025 to USD 9.1 billion by 2035, at a CAGR of 7.5%. ALT Test will dominate with a 44.2% market share, while automated analyzers will lead the technology segment with a 53.3% share.